Literature DB >> 8959535

Cerebral haemorrhage complicating adult-onset Still's disease: a case report.

H Kurabayashi1, K Kubota, K Tamura, T Shirakura.   

Abstract

The case of a 75-year-old Japanese woman with adult-onset Still's disease who presented with cerebral haemorrhage is described. She had been in clinical remission for 2 years, after induction therapy including non-steroidal anti-inflammatory drugs, prednisolone, cyclophosphamide and mizoribine followed by auranofin, until her cerebral haemorrhage occurred, although her serum level of ferritin had gradually increased. After the onset of cerebral haemorrhage, the patient's serum level of thrombomodulin was elevated although c-reactive protein and lactate dehydrogenase were not increased. Anti-cardiolipin antibody and lupus anti-coagulant were not detected. Patients with adult-onset Still's disease are rarely reported to develop cerebral vascular disease, possibly because the disease is most frequent in young adults. The cerebral haemorrhage may have been caused by the vasculitis due to Still's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959535     DOI: 10.1177/030006059602400608

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Portal vein thrombosis in adult-onset Still's disease: a case report and literature review.

Authors:  Hiroyuki Morita; Hiroki Nishiwaki; Yoshikuni Nagayama; Ashio Yoshimura
Journal:  Rheumatol Int       Date:  2009-03-21       Impact factor: 2.631

2.  Adult onset Still's disease in the elderly: a case-based literature review.

Authors:  Arash Mollaeian; Jingjing Chen; Nina N Chan; Gregory A Nizialek; Christopher J Haas
Journal:  BMC Rheumatol       Date:  2021-04-20

3.  Adult-onset Still's disease with concurrent acute necrotizing encephalopathy: a case report.

Authors:  Xue Yang; Meiling Wei; Shuguang Chu; Yue Zhang
Journal:  BMC Neurol       Date:  2022-09-01       Impact factor: 2.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.